Main considerable factors for correct laboratory test interpretation under DOA treatment.

about

Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.A critical appraisal of one-stage and chromogenic assays of factor VIII activity.

P2860

Q33854667-B2FC4B7B-BC37-45FD-91A1-B9D61CC3E4FA Q38668506-9C501EC5-C34A-4E48-87D0-686862E20FB1

P2860

Main considerable factors for correct laboratory test interpretation under DOA treatment.

Item

http://www.wikidata.org/entity/Q42862770

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@en

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@nl

type

Item

label

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@en

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@nl

prefLabel

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@en

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@nl

P1476

Main considerable factors for correct laboratory test interpretation under DOA treatment.

@en

P2093

Edelgard Lindhoff-Last

http://www.w3.org/2001/XMLSchema#string

Helen Mani

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Assays for measuring rivaroxaban: their suitability and limitations.

Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.

P2888

1477-9560-11-22

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1477-9560-11-22

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Edelgard Lindhoff-Last

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258213038

http://www.w3.org/2001/XMLSchema#string

P6179

1051959247

http://www.w3.org/2001/XMLSchema#string

P698

24176012

http://www.w3.org/2001/XMLSchema#string

P932

3842690

http://www.w3.org/2001/XMLSchema#string

Main considerable factors for correct laboratory test interpretation under DOA treatment.

about

P2860

P2860

Main considerable factors for correct laboratory test interpretation under DOA treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932